Literatur
-
1 Rieckmann P, Toyka K V. Leitlinie Diagnostik und Therapie der Multiplen Sklerose. Herausgegeben von der Kommission der Dt. Gesellschaft für Neurologie (DGN), der Dt. Multiple Sklerose Gesellschaft (DMSG) und der Multiple Sklerose Therapie Konsensusgruppe (MSTKG). In: H.C. Diener, ed. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme 2005
-
2
Multiple Sklerose Therapie Konsensusgruppe (MSTKG) .
Immunmodulatorische Stufentherapie der multiplen Sklerose.
2006;
77
1506-1518
-
3
Multiple Sklerose Therapie Konsensusgruppe (MSTKG) .
Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung, März 2002.
Nervenarzt.
2002;
73
556-563
-
4
Rieckmann P, Toyka K V, Bassetti C. et al .
Escalating immunotherapy of multiple sclerosis-new aspects and practical application.
J Neurol.
2004;
251
1329-1339
-
5
Weinshenker B G, O’Brien P C, Petterson T M. et al .
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.
Ann Neurol.
1999;
46
878-886
-
6
Keegan M, Pineda A A, McClelland R L. et al .
Plasma exchange for severe attacks of CNS demyelination: predictors of response.
Neurology.
2002;
58
143-146
-
7
Keegan M, Konig F, McClelland R. et al .
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.
Lancet.
2005;
366
579-582
-
8
The IFNB Multiple Sclerosis Study Group .
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Neurology.
1993;
43
655-661
-
9
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group .
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.
Lancet.
1998;
352
1498-1504
-
10
Jacobs L D, Cookfair D L, Rudick R A. et al .
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Ann Neurol.
1996;
39
285-294
-
11
Comi G, Filippi M, Barkhof F. et al .
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Lancet.
2001;
357
1576-1582
-
12
Jacobs L D, Beck R W, Simon J H. et al .
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
N Engl J Med.
2000;
343
898-904
-
13
Kappos L, Polman C H, Freedman M S. et al .
Treatment with interferon-beta-lb delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Neurology.
2006;
67
1242-1249
-
14
Rovaris M, Confavreux C, Furlan R. et al .
Secondary progressive multiple sclerosis: current knowledge and future challenges.
Lancet Neurol.
2006;
5
343-354
-
15
Comi G, Filippi M, Wolinsky J S.
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Ann Neurol.
2001;
49
290-297
-
16
Johnson K P, Brooks B R, Cohen J A. et al .
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Neurology.
1995;
45
1268-1276
-
17
Polman C H, O’Connor P W, Havrdova E. et al .
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
N Engl J Med.
2006;
354
899-910
-
18
Rudick R A, Stuart W H, Calabresi P A. et al .
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
N Engl J Med.
2006;
354
911-923
-
19
Yousry T A, Major E O, Ryschkewitsch C. et al .
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
N Engl J Med.
2006;
354
924-933
-
20
Yudkin P L, Ellison G W, Ghezzi A. et al .
Overview of azathioprine treatment in multiple sclerosis.
Lancet.
1991;
338
1051-1055
-
21
Sorensen P S, Fazekas F, Lee M.
Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
Eur J Neurol.
2002;
9
557-563
-
22
Stangel M, Gold R.
Einsatz von i. v. Immunglobulinen in der Neurologie Evidenzbasierter Konsens.
Nervenarzt.
2004;
75
801-815
-
23
Achiron A, Kishner I, Dolev M. et al .
Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.
J Neurol.
2004;
251
1133-1137
-
24
Stangel M, Gold R, Gass A. et al .
Current issues in immunomodulatory treatment of multiple sclerosis - a practical approach.
J Neurol.
2006;
253(pt 1)
I32-I36
-
25
Apel A, Greim B, Konig N, Zettl U K.
Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis.
J Neurol.
2006;
253
1131-1136
-
26
Edan G, Miller D, Clanet M. et al .
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
J Neurol Neurosurg Psychiatry.
1997;
62
112-118
-
27
Hartung H P, Gonsette R, Konig N. et al .
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
Lancet.
2002;
360
2018-2025
-
28
Krapf H, Morrissey S P, Zenker O. et al .
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Neurology.
2005;
65
690-695
-
29
Ghalie R G, Edan G, Laurent M. et al .
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.
Neurology.
2002;
59
909-913
-
30
Zingler V C, Strupp M, Jahn K, Gross A, Hohlfeld R, Brandt T.
Kombinierte Mitoxantron-/Methylprednisolon-Behandlung bei primar und sekundar chronisch progredienter Multipler Sklerose. Eine Anwendungsbeobachtung bei 65 Patienten.
Nervenarzt.
2005;
76
740-747
-
31
Henze T.
Symptomatische Therapie der Multiplen Sklerose.
Nervenarzt.
2004;
75 (pt 1)
2-39
Priv.-Doz. Dr. med. Andreas Steinbrecher
Neurologische Universitätsklinik Regensburg
Universitätsstraße 84
93053 Regensburg
Email: andreas.steinbrecher@medbo.de
